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Abstract 35 
 36 
Since the concept of continuous processing is gaining momentum in pharmaceutical 37 
manufacturing, a thorough understanding on how process and formulation parameters can 38 
impact the critical quality attributes (CQA) of the end product is more than ever required.  This 39 
study was designed to screen the influence of process parameters and drug load during HME 40 
on both extrudate properties and tableting behaviour of an amorphous solid dispersion 41 
formulation using a quality-by-design (QbD) approach. A full factorial experimental design with 42 
19 experiments was used to evaluate the effect of several process variables (barrel 43 
temperature: 160-200 °C, screw speed: 50-200 rpm, throughput: 0.2-0.5 kg/h) and drug load 44 
(0-20%) as formulation parameter on the hot-melt extrusion (HME) process, extrudate and 45 
tablet quality of Soluplus®-Celecoxib amorphous solid dispersions. A prominent impact of the 46 
formulation parameter on the CQA of the extrudates (i.e. solid state properties, moisture 47 
content, particle size distribution) and tablets (i.e. tabletability, compactibility, fragmentary 48 
behaviour, elastic recovery) was discovered. The resistance of the polymer matrix to thermo-49 
mechanical stress during HME was confirmed throughout the experimental design space. In 50 
addition, the suitability of Raman spectroscopy as verification method for the active 51 
pharmaceutical ingredient (API) concentration in solid dispersions was evaluated. 52 
Incorporation of the Raman spectroscopy data in a PLS model enabled API quantification in 53 
the extrudate powders with none of the DOE-experiments resulting in extrudates with a CEL 54 
content deviating > 3 % of the label claim. This research paper emphasized that HME is a 55 
robust process throughout the experimental design space for obtaining amorphous glassy 56 
solutions and for tabletting of such formulations since only minimal impact of the process 57 
parameters was detected on the extrudate and tablet properties. However, the quality of 58 
extrudates and tablets can be optimized by adjusting specific formulations parameters (e.g. 59 
drug load).  60 
 61 
Keywords: Hot-melt extrusion (HME), tableting, Quality by Design, solid dispersion, tablet 62 
quality, Raman spectroscopy, Principle component analysis (PCA).  63 
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1.    INTRODUCTION 64 
 65 
With the increasing number of new chemical entities being classified as poorly water-66 
soluble, pharmaceutical industry and academia have found themselves a major challenge 67 
how to formulate these drug candidates into potent immediate release solid dosage forms. 68 
The concept of solubility enhancement through the formation of amorphous solid 69 
dispersions has been widely explored for this purpose whereby the drug molecules are 70 
dispersed within a solid polymeric matrix. From the broad range of processing techniques 71 
which have been used in the last decades for solid dispersion manufacturing (Janssens 72 
and Van den Mooter, 2009; Leuner and Dressman, 2000; Paudel et al., 2013; Sethia and 73 
Squillante, 2004), hot-melt extrusion (HME) proved extremely suitable since it does not 74 
require solvents or water, thereby avoiding potential water-mediated drug degradation or 75 
time-consuming drying steps (Saerens et al., 2013). Polymer and API are fed into a heated 76 
barrel with screws and the combination of heat, mixing and shear finally results in a 77 
homogeneous melt where the drug is preferably molecular dispersed in the polymer matrix 78 
(Sarode et al., 2013; Shah et al., 2013). With the efforts made by the pharmaceutical 79 
industry to gradually shift the focus from batch towards continuous processing, HME 80 
steadily (re-)gained interest since the technique enables superior mixing (both distributive 81 
and dispersive) despite the short residence time, allows several downstream options 82 
towards various dosage forms and can be run in continuous mode (Plumb, 2005; Saerens 83 
et al., 2013; Vervaet et al., 2013). However, there is still insufficient understanding of the 84 
critical formulation and process parameters during the HME process of specific 85 
pharmaceutical formulations which is reflected in the limited number of pharmaceutical 86 
products available on the market processed by HME. Initiated by the Food and Drug 87 
Administration (FDA) in order to increase the robustness and quality of a product, 88 
pharmaceutical quality-by-design (QbD) was introduced as a strategic product 89 
development approach which considers both formulation and process-related factors that 90 
affect the critical quality attributes of the final product (Patwardhan et al., 2015). This 91 
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already resulted in a few interesting approaches to implement QbD in pharmaceutical melt 92 
extrusion processes (Agrawal et al., 2016; Islam et al., 2014; Patwardhan et al., 2015).  93 
In a previous article (Grymonpré et al., 2017), glassy solutions of amorphous polymers 94 
with Celecoxib (CEL) were made by HME and further downstream processed via milling 95 
and compression into tablets. A polymer platform for HME/tableting purpose was 96 
successfully established from which an adequate polymer could be selected. These glassy 97 
solutions showed a high milling efficiency and excellent tableting properties, supporting the 98 
high potential of HME for implementation in a continuous manufacturing line. In the current 99 
research study, a promising polymer-drug combination (using Soluplus® as polymer and 100 
Celecoxib as poorly soluble drug) was selected from the platform and subjected to a QbD 101 
approach to thoroughly understand how process (barrel temperature, screw speed, 102 
throughput) and formulation (drug load) parameters can influence the critical quality 103 
attributes of extrudates and tablets prepared from these amorphous solid dispersions.  104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
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2.    MATERIALS AND METHODS 119 
2.1.  Materials  120 
Soluplus® (SOL) was selected for this study as amorphous polymer and kindly donated 121 
by BASF (Ludwigshafen, Germany). Celecoxib (CEL, Utag, Amsterdam, The Netherlands), a 122 
BCS class II drug, was used as model drug.     123 
2.2.   Hot-melt extrusion  124 
  125 
 HME experiments were performed using a co-rotating, fully intermeshing twin-screw 126 
extruder (Prism Eurolab 16, Thermo Fisher, Germany) equipped with a DD Flexwall 127 
gravimetric feeder (Brabender Technology, Germany), two co-rotating twin-screws with 3 128 
mixing zones (length to diameter ratio L/D=25) and a cylindrical die of 3 mm. A data logging 129 
system allowed monitoring of the screw torque and barrel well temperature during extrusion. 130 
The extrusion barrel is divided into 6 segments which can be heated/cooled separately. Barrel 131 
temperature from segment 1 to 5 were set at the same temperature (the actual temperature 132 
depended on the experiment as the extrusion temperature was included as a variable in the 133 
study), while the die temperature was 140 °C for all experiments to guarantee a solid end 134 
product. For each run, 300 g of extrudates were collected at steady state extrusion conditions. 135 
After cooling, the extrudates were milled using a knife mill (Moulinex AR110510, France) for 136 
60 s and sieved through a 150 m sieve.  137 
2.3. Preparation of tablets  138 
 Direct compression of the milled extrudates was performed on a rotary tablet press 139 
(MODULTM P, GEA Pharma Systems, CourtoyTM, Halle, Belgium) equipped with cylindrical flat-140 
faced Euro B punches of 10 mm diameter and an overfill cam of 16 mm. Tablets of 141 
approximately 270 mg were produced at 3 main compaction pressures: 127 ( 9.1), 255 ( 142 
19.2) and 382 ( 27.0) MPa at a turret speed of 5 rpm without using a pre-compression step. 143 
Punch deformation at each compaction pressure was calculated and corrected for during this 144 
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study. All tablets were analysed for ‘out-of-die’ properties (tablet strength, dimensions and 145 
mass) immediately after ejection.  146 
In-die measurements of the compaction properties was performed by linear variable 147 
displacement transducers (LVDT) incorporated inside the turret and clamped onto one pair of 148 
punches enabling the monitoring of punch stroke movements during a compression cycle 149 
(GEA Pharma Systems, Halle, Belgium). Calibration was done prior to each experiment, by 150 
interpolating the output voltage of the sensor to physical values during static measurements. 151 
A wireless transmission system continuously transmitted the data from these sensors to a data 152 
acquisition and analysis system (CDAAS™, GEA Pharma Systems, Halle, Belgium).  153 
2.4. Design of experiments  154 
 The experimental ranges for the DOE factors barrel temperature, screw speed, 155 
throughput and drug load were determined based on preliminary experiments. A two-level full 156 
factorial design with 16 experiments was applied to evaluate the influence of three process 157 
parameters: barrel temperature (160-200 °C), screw speed (50-200 rpm), throughput (0.2-0.5 158 
kg/h) and one formulation parameter: drug load (0-20 %) on the HME process and tableting 159 
behaviour of the resulting extrudates. Three centerpoint replicates were executed to evaluate 160 
the reproducibility. An overview of the experiments is given in Table 1. The responses were 161 
regressed against the factors via multiple linear regression (MLR) using MODDE 10.1. 162 
software (Umetrics, Umeå, Sweden) where all factors were scaled and centered making the 163 
regression coefficients comparable for the different factors. 95% confidence intervals were 164 
included for each effect in order to evaluate if factors or factor interactions were significant (i.e. 165 
95% confidence interval of the corresponding effect not including zero). 166 
2.5. Evaluation of the HME process  167 
 At each extrusion condition, the torque on the screws was recorded after reaching 168 
steady state conditions and the specific mechanical energy (SME) calculated to evaluate the 169 
HME process. A reading of 100 % corresponded to the maximum allowable torque of 14.2 Nm. 170 
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Prior to each run, the friction torque was determined by running the extruder with screws 171 
attached and the barrel empty at the specific conditions as given in Table 1. This friction torque 172 
was subtracted from the total recorded torque to obtain the net torque (Godavarti and Karwe, 173 
1997). The SME represents the level of energy per mass unit that is transferred to the material 174 
by mechanical input during extrusion (Domenech et al., 2013) and was calculated as follows 175 
(Martin, 2013):  176 
 177 
				SME	ሺKWh/kgሻ	ൌ	ሺ݉݋ݐ݋ݎ	ݎܽݐ݅݊݃ሻ	ݔ	ሺ݊݁ݐ	ݐ݋ݎݍݑ݁ሻݔ	 ேே௠௔௫		௫	௧௛௥௢௨௚௛௣௨௧ 	ݔ	݃݁ܽݎܾ݋ݔ	݂݂݁݅ܿ݅݁݊ܿݕ							ሺ1ሻ 178 
 179 
where the extruder had a motor rating of 1.5 KW and a maximum screw speed (Nmax) of 500 180 
rpm. Net torque (%), operational screw speed (N) and throughput (kg/h) varied based on the 181 
experimental settings. Regarding the technical specification of the extruder drive, the gearbox 182 
efficiency was set at 0.95.  183 
2.6. Evaluation of extrudates  184 
2.6.1. Thermal analysis  185 
 186 
 Modulated Differential Scanning Calorimetry (MDSC) measurements were performed 187 
both after HME and milling in order to verify the solid state properties of all formulations after 188 
each processing step. A heating rate of 2 °C/min and a modulation of 0.318 °C/min over 2 189 
cycles (heat/cool/heat) from -20 to 200 °C was used. The MDSC cell was purged with dry 190 
nitrogen at a flow rate of 50 ml/min. Three samples of each experimental run were analysed 191 
using the TA instruments Universal Analysis 2000 software.  192 
2.6.2. Particle size analysis  193 
 194 
 Particle size distribution (PSD) of the powders was recorded (n=3) by laser diffraction 195 
(Mastersizer-S long bench, Malvern Instruments, Malvern, UK) via a dry dispersion method in 196 
volumetrical distribution mode using a 300 RF lens combined with a dry powder feeder at a 197 
feeding rate of 3.0 G and a jet pressure of 2.0 bar (Malvern Instruments, Malvern, UK).  198 
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 199 
 200 
2.6.3. Moisture content  201 
 202 
 Immediately before tabletting, loss on drying (LOD) was performed (n=3) on the 203 
powders corresponding to each experimental run to determine residual moisture content using 204 
a Mettler LP16 moisture analyser, including an infrared dryer and a Mettler PM460 balance 205 
(Mettler-Toledo, Zaventem, Belgium). Approximately 1 g of sample was dried at 105 °C until 206 
the rate of change was less than 0.1% w/w for 30 s. 207 
2.6.4. Flowability  208 
 209 
The flow rate of the powders was determined using a flowability testing device 210 
(FlowPro, IPAT, Finland) which consists of a frame, sample holder (5.96 ml) with orifice (3.0 211 
mm) and an analytical scale. Vertical oscillations of the sample holder break the cohesive 212 
forces in the powder bed and allow the powder to flow through the orifice. The mass discharged 213 
from the sample holder is measured over time in order to calculate the flow rate (mg/s) (Sandler 214 
et al., 2010). 5% of the mass flow function at the beginning and at the end was not taken into 215 
account to minimize the non-linearity of the mass flow (Seppälä et al., 2010). All samples were 216 
measured in triplicate. 217 
2.6.5. Size Exclusion Chromatography  218 
  219 
 Molecular weight distribution analysis was applied to verify if the HME settings used in 220 
this experimental design influenced this property of the polymer. Size exclusion 221 
chromatography (SEC) measurements were performed on a Shimadzu 20A system using 222 
dimethylacetamide (DMAc) supplemented with 50 mM LiBr as mobile phase. The system was 223 
equipped with a 20A ISO-pump and a 20A refractive index detector (RID). Measurements were 224 
recorded at 50 °C with a flow rate of 0.700 mL/min. Calibration of the 2 PL 5 μm Mixed-D 225 
columns was done with poly(methyl methacrylate) (PMMA) standards obtained from PSS 226 
(Mainz, Germany). Samples were run with toluene as an internal standard. All formulations of 227 
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the experimental design space without CEL (exp. 1-8) were analysed in triplicate together with 228 
the neat (non-processed) polymer. In addition, a SOL sample, processed at elevated 229 
temperatures (350 °C) to maximize the stress on the polymer, was analysed in order to verify 230 
if the technique was able to detect changes in the polymer molecular weight.   231 
2.6.6. Raman spectroscopy  232 
 233 
A calibration model was developed allowing off-line API quantification in the extrudates 234 
using Raman spectroscopy. Nine different SOL-CEL mixtures, containing 5, 10, 18, 19, 20, 21, 235 
22, 30 and 40 % (w/w) CEL, were extruded at centerpoint-settings (Table 1) and milled to 236 
powders. Five validation mixtures of SOL-CEL, containing 19, 20, 21, 25 and 35 % drug were 237 
extruded at the same extrusion parameters to evaluate the suitability of Raman spectroscopy 238 
for off-line CEL quantification in glassy solutions. A Raman Rxn2 spectrometer (Kaiser Optical 239 
Systems, Ann Arbor, MI, USA), equipped with a fibre-optic PhAT-probe was used for collection 240 
of the Raman spectra. The laser wavelength was 785 nm and the spectra were recorded with 241 
a resolution of 5 cm-1. For all the formulations an exposure time of 5 s with no averaging was 242 
used. The analysed spectral region was 665-1655 cm-1, since this region contained all useful 243 
drug and polymer information. Data analysis was performed using SIMCA 13.0.3 (Umetrics, 244 
Umeå, Sweden). First derivative pre-processing was applied on the collected spectra of all 245 
formulations before principal components analysis (PCA) and partial least squares analysis 246 
(PLS). At least 6 spectra of each formulation were used to develop the PLS model, regressing 247 
the CEL concentrations (Y) versus the corresponding Raman spectra (X). Validation and 248 
uncertainty estimation of the quantitative analytical procedure was performed calculating the 249 
following parameters (Li et al., 2011; Saerens et al., 2014):  250 
 251 
- Root mean square error of prediction:   252 
RMSEP	ൌ	ටቀ∑ ሺ௬೔‐௬ො೔ሻమூூ௜ୀଵ ቁ		 	 	 	 	 							ሺ1ሻ	253 
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where I represent the number of samples, yi and ŷi the reference and Raman predicted value 254 
for sample i, respectively.  255 
- Relative bias:   256 
Relative	Bias	ሺ%ሻൌ	ቀሾ௫ഥ݅ ିఓሿఓ ቁ ݔ100	 	 	 	 					ሺ2ሻ 257 
with ݔഥ݅  and µ being the average measured API concentration and the true value of the 258 
sample, respectively.  259 
- Relative standard deviation:  260 
				RSD	ሺ%ሻൌ	ቀሾ௦	௫	ଵ଴଴ሿݔഥ݅ ቁ		 	 	 	 	 					ሺ3ሻ 261 
where s denotes the standard deviation on the measured API concentrations of repeated 262 
samples whereas ݔഥ݅  represents the average measured API concentration of those samples.  263 
  264 
2.7. Evaluation of the tableting behaviour  265 
2.7.1. Out-of-die tablet properties  266 
 267 
Tablet diametral tensile strength was calculated using the equation described by Fell 268 
and Newton (1968):    269 
          Tablet	Tensile	Strength	ሺσt	ሻ	ൌ	 ଶ௉గ஽௧                      (4) 270 
where P, D and t denotes tablet diametral breaking force (N), tablet diameter (mm) and tablet 271 
thickness (mm), respectively, which are determined using a hardness tester (Sotax HT10, 272 
Basel, Switzerland).  273 
 274 
 275 
In order to determine the porosity of the compacts following equation is used:  276 
     Tablet	Porosity	ൌ	1 െ	 	ఘೌ೛೛	ఘ೟ೝೠ೐                        (5) 277 
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where ρapp and ρtrue denote the apparent and true density (g/ml), respectively. The latter was 278 
measured using helium pycnometry (AccuPyc 1330, Micrometrics, Norcross, USA), while the 279 
apparent density was calculated by dividing the tablet mass by the volume of the tablet.  280 
Out-of-die elastic recovery (ER) of the compacts was calculated based on following 281 
equation (Armstrong and Haines-Nutt, 1972):   282 
                 ܧܴ	ሺ%ሻ ൌ ቀ	்௔ି	்௜ௗ்௜ௗ ቁ ݔ100             (6) 283 
for which Tid represents the minimal tablet thickness (mm) under maximal compression force 284 
‘in-die’ and Ta is the tablet thickness (mm) measured immediately after ejection.  285 
2.7.2. In-die tablet properties  286 
 287 
 Energy plots (i.e. force-displacement curves) were recorded during the compression 288 
cycles which enabled the calculation of the energy consumption or dissipation at each phase 289 
from the area under the curve (Michaut et al., 2010):       290 
       ܧ ൌ 	׬ ܨ	݄݀          (7) 291 
where F denotes the compression force (kN) and h the punch separation (mm). All energies 292 
are normalised by taking the compact mass into account to allow comparison between the 293 
different formulations. Resulting energies are used for calculating two specific compaction 294 
properties:   295 
‐ A plasticity factor (PF) which represents the energy of compaction used for plastic 296 
deformation and fragmentation:  297 
    ܲܨ	ሺ%ሻ ൌ 	 ௡௘௧	௘௡௘௥௚௬௧௢௧௔௟	௘௡௘௥௚௬ 	ݔ	100                  (8) 298 
‐ In-die elastic recovery (IER) which represents the elasticity of a material:  299 
    ܫܧܴ	ሺ%ሻ ൌ 	 ்೏ି ೎்
೎்
	ݔ	100         (9) 300 
where Td and Tc represents the punch separation after decompression and the minimal 301 
punch separation during compression, respectively.   302 
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All calculations for in-line measuring the compaction properties were done using the CDAAS™ 303 
software (GEA Pharma Systems, Halle, Belgium) on at least 3 compacts for each formulation. 304 
Using the in-die data of the CDAAS™ system, Heckel analysis was performed on all 305 
formulations using the data at a compaction pressure of approximately 65 MPa. The theory of 306 
Shapiro-Konopicky-Heckel is based on following equation (Heckel, 1961):  307 
     ݈݊	 ଵா ൌ ܭܲ ൅ ܣ                   (10) 308 
where E is the porosity of the powder bed at a compaction pressure P, K is the slope of the 309 
linear part of the plot (with the best R2 fit) and A is the Y intercept with the linear part of the 310 
plot. The mean Heckel yield pressures (Py) are given by the reciprocal values K, while the 311 
intercept of both the linear part of the plot (A) and the non-linear part (I) are used to calculate 312 
Da, DI.  313 
   Da	ሺIሻ	ൌ	1‐	݁ି஺	ሺூሻ		 	 	 	 	 			(11)	314 
The difference between Da and DI denotes Db, which describes the reduction in volume due to 315 
rearrangement of the particles since A is said to reflect low pressure densification by 316 
interparticulate motion (Tarlier et al., 2015).  317 
           Db	ൌ	Da	–	DI		 	 	 	 	 					(12) 318 
 319 
2.7.3. Multivariate data analysis  320 
 321 
Principal component analysis (PCA) was executed on the relevant compaction data in 322 
order to classify the different materials according to their compaction behaviour using the 323 
multivariate data analysing software SIMCA 13.0.3 (Umetrics, Umeå, Sweden). PCA is a 324 
multivariate projection method which extracts and displays the variation in the data set (Pieters 325 
et al., 2013). The data were pre-processed by unit variate scaling and centered in order to 326 
balance the weight of each variable.  327 
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3.    RESULTS AND DISCUSSION 328 
3.1.  Evaluation of the HME process   329 
 Although the torque values strongly varied in function of the experimental parameters, 330 
none of them exceeded 55 % of the maximum torque tolerated by the extruder (Table 2). 331 
Torque was mainly influenced by barrel temperature and drug load (Fig. 1) since both factors 332 
impact the melt viscosity of the formulation. Higher barrel temperatures reduced the melt 333 
viscosity of the formulation and therefore less energy input was required to rotate the screws 334 
at a predefined screw speed. The latter also occurred when adding CEL to the formulation, 335 
since the API can act as a plasticizer when solubilized in the polymer matrix, yielding lower 336 
torque values. These findings were confirmed by analyzing rheological data of SOL-CEL 337 
formulations as previously reported (Grymonpré et al., 2017).  338 
 339 
Calculation of SME values during the HME process has proven its value in previous 340 
research as a variable to quantify mixing in an extruder (Sakai and Thommes, 2013), linking 341 
the HME process parameters with thermo-mechanical degradation (Wang et al., 2008) or as 342 
key descriptor of the influence of processing on the dispersion state (Domenech et al., 2013). 343 
Therefore, SME was added in this research as response of the experimental design (Table 2). 344 
The impact of process and formulation parameters on the SME levels during HME is 345 
represented by the effect plot in Fig. 2. An effect plot displays the change in the response when 346 
a factor varies from its low level (-1) to its high level (+1), with all other factors kept constant at 347 
their average values. Increasing the screw rotational speed during HME contributed 348 
significantly to higher SME-levels, indicating that more mechanical energy is transferred to the 349 
material under such conditions. Factors that reduced the torque such as higher barrel 350 
temperatures and drug load resulted in lower SME-levels caused by a decrease of the matrix 351 
viscosity under such conditions. When more material is fed into the barrel at fixed settings, the 352 
same amount of energy must be transferred to a larger amount of material, thereby reducing 353 
SME values.  354 
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3.2.  Evaluation of the extrudates  355 
 For the experiments including CEL as model drug, changing the process parameters 356 
during HME had no impact on the solid dispersion type. Glassy solutions were obtained at 357 
every condition, indicating the suitability of SOL as polymeric carrier for CEL solid dispersions. 358 
This is in accordance to previous research where stable amorphous solid dispersions of SOL-359 
CEL were made with drug loads up to 35 % (Grymonpré et al., 2017).  In this experimental 360 
design, the drug load ranged from 0 to 20 % since preliminary experiments pointed out that 361 
higher drug loads decreased the flow properties of the physical mixtures, thereby hampering 362 
the ability of including the throughput as factor in the DOE. As throughput was an important 363 
process parameter under investigation in this research paper, a consensus was made by 364 
lowering the drug load (i.e. formulation parameter), enabling a profound screening design 365 
including both process and formulation parameters.  366 
Higher drug loads reduced the glass transition temperature (Tg) of the resulting 367 
extrudates, as CEL acted as plasticizer, while the process parameters had no significant 368 
impact on solid state properties of the glassy solutions (Fig. 3). Similar conclusion was drawn 369 
after analysis of the particle size distribution (PSD) of the milled extrudates: d50 and d90 values 370 
increased for extrudates containing higher drug load (Fig. 3). Due to the drop in Tg, the material 371 
was less brittle during milling at room temperature compared to extrudates without CEL. 372 
However, these differences had no impact on the flow properties of the milled formulations, 373 
enabling further downstream processing such as (continuous) feeding of a rotary tablet press 374 
during tableting. Significant impact of drug load and barrel temperature was detected on the 375 
moisture content of the milled extrudates (Fig. 4). When formulating glassy solutions with high 376 
drug loads, the moisture content decreases significantly when higher extrusion temperatures 377 
are used. It has been described in literature that adsorption of water in dense glassy particles 378 
occurs mainly at the surface (via weak interactions) due to the absence of pores penetrable to 379 
water (Jouppila, 2006). The level of densification during HME might be influenced by the 380 
extrusion temperature at higher drug loads, as smaller amorphous clusters or a more extensive 381 
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molecular dispersion are created at elevated extrusion temperatures. Density of the extrudates 382 
was indeed higher with increasing drug loads and therefore this could explain the observed 383 
impact of extrusion temperature on the moisture content at higher drug loads. Although the 384 
effects in this study were relatively small (e.g. maximal deviation of 0.4 %) and the impact of 385 
moisture content was not reflected in the tableting behaviour of the formulations, it is an 386 
important observation since these effects could be more pronounced for other formulations. In 387 
general, it could be concluded that drug load had the most significant impact on the extrudates 388 
properties, indicating that for this specific formulation the HME process was very robust.  389 
Commonly in literature, little attention is paid to the influence of processing techniques 390 
and settings on the polymer matrix, despite the evidence that extrusion can modify the polymer 391 
structure (Alexy et al., 2004; Capone et al., 2007). Molecular weight distribution (MWD) 392 
analysis of polymers provided insight into possible thermo-mechanical degradation of SOL 393 
during by the HME-process. MWD of extrudates resulting from runs with high, low and medium 394 
SME-values (exp. 3, 2 and 4, respectively), which represent the thermo-mechanical energy 395 
input during the extrusion process (Wang et al., 2008), were plotted against MWD of non-396 
processed and deliberately stressed SOL in Fig. 5. The method used was able to detect 397 
changes in the MWD of SOL based on the peak broadening of the ‘stressed’ samples towards 398 
low and high molecular weight species. It is hypothesized that heat-induced side chain 399 
hydrolysis and cross-linking caused these changes in the ‘stressed’ SOL sample. However, no 400 
significant changes in MWD of SOL were detected under the conditions employed in the 401 
experimental design space. These findings confirmed the resistance of SOL towards thermo-402 
mechanical stress during HME at regular extrusion settings.  403 
In order to quantify the concentration of CEL in the extrudates, off-line Raman 404 
spectroscopy was applied on powders of the formulations containing API (exp. 9-19, Table 1). 405 
MDSC and XRD measurements confirmed the absence of crystalline CEL in each formulation, 406 
indicating the formation of glassy solutions comparable to the DOE-formulations. The 407 
concentration variations are clearly visible in the collected Raman spectra (Fig. 6, above) which 408 
is reflected in the PCA scores plot of the collected spectra (Fig. 6, lower). The two principle 409 
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components covered nearly all spectral variation, where the first principal component (PC1) 410 
accounted for 96 % of the total variation. It was confirmed from the scores plot that PC1 411 
captured the spectral variation caused by differences in API-polymer concentration since a 412 
clear distinction can be made between the Raman spectra of the calibration set.  413 
A PLS model was developed which allowed prediction of the CEL concentration in the 414 
extrudate powders of the DOE-formulations by regressing the off-line collected spectra (X) of 415 
the calibration set versus the known CEL concentrations (Y). Two PLS components were 416 
sufficient since the goodness of prediction of the model (Q2=0.996) did not significantly 417 
increase when adding extra components. The predictive performance of the PLS model was 418 
validated by projecting the Raman spectra of a validation set onto the model in order to predict 419 
the corresponding CEL concentrations (Fig. 7). This resulted in a root mean square error of 420 
prediction (RMSEP) of 1.84 %. For each validation concentration level, accuracy was 421 
evaluated by calculating the trueness and precision (Table 3). A good precision of the method 422 
was noticed as the accuracy of all validated concentrations remained within the acceptance 423 
limits of 10 % (Saerens et al., 2014). The latter PLS model enabled quantification of CEL (%) 424 
in the extrudate powders of correlating experiments of the experimental design (Table 4). None 425 
of the experiments in the DOE resulted in extrudates with a CEL content deviating > 3 % of 426 
the label claim, taking into account the RMSEP.  427 
 428 
 429 
 430 
 431 
3.3. Influence of the design variables on the tableting behaviour  432 
3.3.1. Out-of-die tablet properties 433 
  434 
 Tabletability was clearly affected by the drug load as can be seen in Fig. 8 (full vs. 435 
dotted lines), while changing the process parameters had no significant impact on this tablet 436 
property. Tablets manufactured from extrudates formulated with CEL yielded significantly 437 
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higher tensile strengths. Additionally, the shape of the curves was influenced by the formulation 438 
parameter as the tabletability of formulations without drug was independent of the compaction 439 
pressure, while CEL-containing formulations showed an inflection point prior to reaching the 440 
‘plateau’ phase at higher main compaction pressures. The latter indicated that changes in the 441 
mechanical properties of these formulations had occurred, which resulted in tablets of higher 442 
tensile strength.  443 
 444 
Some of the provided energy during compaction can be stored by materials as elastic 445 
energy, which is linked to the elastic recovery during decompression thereby causing 446 
disruption of some of the previously formed interparticulate bondings (Sun and Grant, 2001). 447 
Fig. 9 represents how process and formulation parameters influence the magnitude of this out-448 
of-die descriptor, with an inverse correlation between drug load and out-of-die elastic recovery. 449 
Low values of the latter are preferred, since the phenomenon of capping was linked to 450 
modifications in the compact during the decompression phase (Wu et al., 2008) and low out-451 
of-die elastic recoveries are beneficial within the context of continuous tablet coating after 452 
ejection.  453 
3.3.2.  In-die tableting properties  454 
 455 
 Previously, we have highlighted the added value of including in-die compaction 456 
properties to comprehensively investigate the tableting behaviour of materials since this 457 
provided better insight in the compression mechanisms which enable the formation of strong 458 
compacts. The compaction properties plasticity factor (PF) and in-die elastic recovery (IER), 459 
calculated from the recorded energy plots during a compression cycle, represent the 460 
contribution of respectively plastic deformation and elastic behaviour to the tensile strength of 461 
a tablet. Drug load had a significant impact on the plastic deformation of the formulation, with 462 
higher PF at increasing drug loads, while IER was unaffected by this formulation parameter. 463 
Analysis of the Heckel plots allowed to interpret the volume reduction processes during the 464 
compression phase, where high Py and Db values are indicative for materials undergoing more 465 
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particle rearrangement in the low pressure region (Tarlier et al., 2015). Formulation of glassy 466 
solutions with increasing levels of CEL yielded higher Py and Db values, highlighting the more 467 
fragmentary behaviour of these formulations which contributed to their higher tablet tensile 468 
strengths (Fig. 8). 469 
 470 
 471 
3.3.3. Multivariate data analysis  472 
  473 
 The influence of the design variables on the tableting behaviour was summarized using 474 
principle component analysis (PCA) where different compaction properties and mechanical 475 
properties were included in order to classify formulations of the different experiments according 476 
to the contributions of these individual properties. The two principal components in the PCA 477 
accounted for 82.5 % of the total variance in the dataset, the first principal component (PC1) 478 
comprising 68.5 % of the variance. When analysing the PCA bi-plot (Fig. 10) along PC1, the 479 
prominent influence of the formulation parameter drug load stands out with a cluster of the 20 480 
% CEL formulations having low PC1 values (blue triangles), formulations without drug having 481 
high PC1 values (orange boxes) and the centerpoint formulations with 10 % CEL having 482 
intermediate values (green circles). The loadings indicated that PC1 (i.e. the direction of the x-483 
axis) differentiated between formulations which experienced more fragmentation and plastic 484 
deformation and therefore yielded tablets of higher tensile strength (left of the origin), while it 485 
was anti-correlated with the out-of-die elastic recovery (right of the origin). PC2 (i.e. the 486 
direction of the y-axis) captured the flow properties of the powders and the IER which was anti-487 
correlated to the PF.  488 
4.      CONCLUSIONS 489 
A QbD approach for HME/tableting was successfully implemented in this research 490 
study to evaluate the influence of process parameters and drug load during HME on both 491 
extrudate properties and tableting behaviour of an amorphous solid dispersion formulation. 492 
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Modulation of the torque was possible by adjustment of the barrel temperature and drug load. 493 
Additional variations in screw speed and throughput led to different SME-levels, which 494 
represent the input of mechanical energy into the material during HME. Drug load had the most 495 
significant impact on the extrudate properties with minimal influence of the process variables. 496 
Similar results were obtained when evaluating the tableting behaviour of the formulations with 497 
a prominent influence of the formulation parameter (i.e. drug load) on the compaction and 498 
mechanical properties and no effect of varying HME process parameters. Increasing drug 499 
loads resulted in compacts with higher tensile strength since the volume reduction 500 
mechanisms changed towards more fragmentary behaviour combined with more plastic 501 
deformation and less out-of-die elastic recovery. A PLS model was developed and validated 502 
for Raman spectroscopy data which allowed off-line CEL quantification in the extrudates. This 503 
research emphasized that HME is a robust process throughout the experimental design space 504 
for obtaining amorphous glassy solutions and tablets of such formulations since only minimal 505 
impact was detected of the process parameters on the extrudate and tablet properties. 506 
However, the quality of extrudates and tablets can be optimized by adjusting specific 507 
formulations parameters (e.g. drug load).    508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
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Figure 1. Contour plot of torque as function of barrel temperature (°C) and drug load (%).  642 
Figure 2. Effect plot of SME including 95% confidence intervals for screw speed (Scr), barrel temperature (T), throughput (Thr) 643 
and drug load (Dru) with their interactions (*) as factors. 644 
Figure 3. Effect plots of extrudate properties including 95% confidence intervals: responses Tg (upper figure) and d90 (lower 645 
figure) for screw speed (Scr), barrel temperature (T), throughput (Thr) and drug load (Dru) with their interactions (*) as factors.  646 
Figure 4. Effect plot including 95% confidence intervals of the moisture content (upper figure) for screw speed (Scr), barrel 647 
temperature (T), throughput (Thr) and drug load (Dru) with their interactions (*) as factors while the interaction plot (lower figure) 648 
is highlighting the combined effect of barrel temperature (T) and drug load on the moisture content.     649 
Figure 5. Molecular weight distributions (left) of SOL-samples: non-processed (neat), hot-melt extruded at stress condiditions 650 
(stressed) or hot-melt extruded using different (low, medium and high) SME conditions (EX). The molecular structure of SOL is 651 
shown (right).   652 
Figure 6. Off-line collected Raman spectra with first derivative pre-processing (upper figure) and the corresponding PC1 versus 653 
PC2 scores plot (lower figure) of the calibration set for milled extrudates containing 5 % CEL (black), 10 % CEL (red), 20 % CEL 654 
(blue), 30 % CEL (yellow) and 40 % CEL (green).  655 
Figure 7. Predicted versus observed CEL concentrations of the Raman spectra of the validation set containing 19 % CEL (black 656 
squares), 20 % CEL (red circles), 21 % CEL (blue triangles), 25 % CEL (yellow inverse triangles) and 35 % CEL (green 657 
diamond).  658 
Figure 8. Tabletability plot of all experiments (left) and the effect plot including 95% confidence intervals of the tablet tensile 659 
strength at 255 MPa (right). Formulations without API (experiments 1-8) are represented by dotted lines (), formulations with 660 
20 % drug load (experiments 9-16) are represented by full lines () while the centerpoints containing 10 % drug load 661 
(experiments 17-19) are displayed by dashed lines (-----). 662 
Figure 9. Out-of-die elastic recovery in function of main compaction pressure for all experiments (left) and the corresponding 663 
effect plot including 95% confidence intervals at 255 MPa (right). Formulations without API (experiments 1-8) are represented by 664 
dotted lines (), formulations with 20 % drug load (experiments 9-16) are represented by full lines () while the centerpoints 665 
containing 10 % drug load (experiments 17-19) are displayed by dashed lines (-----). 666 
Figure 10. PC1 vs. PC2 bi-plot of the determined compaction and flow properties for formulations of experiments containing 20 % 667 
CEL (blue triangles), formulations of experiments without drug load (orange boxes) and centerpoints containing 10 % CEL (green 668 
circles) for which the number represents the corresponding experiment number in the experimental design. The loadings (red star 669 
shape) represent the fragmentation factor (Db), the heckel value (Py), the plasticity factor (PF) and the anti-correlated in-die elastic 670 
recovery (IER), tablet tensile strength (TS) and out-of-die elastic recovery (AR) for three compaction pressures (low, medium, 671 
high) and the flow rate of the powder formulations.  672 
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Figure 1. Contour plot of torque as function of barrel temperature (°C) and drug load (%).  
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Figure 2. Effect plot of SME including 95% confidence intervals for screw speed (Scr), barrel temperature (T), throughput 
(Thr) and drug load (Dru) with their interactions (*) as factors.  
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Figure 3. Effect plots of extrudate properties including 95% confidence intervals: responses Tg (upper figure) and d90 (lower figure) for 
screw speed (Scr), barrel temperature (T), throughput (Thr) and drug load (Dru) with their interactions (*) as factors.  
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Figure 4. Effect plot including 95% confidence intervals of the moisture content (upper figure) for screw speed (Scr), barrel temperature 
(T), throughput (Thr) and drug load (Dru) with their interactions (*) as factors while the interaction plot (lower figure) is highlighting the 
combined effect of barrel temperature (T) and drug load on the moisture content.  
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Figure 5. Molecular weight distributions (left) of SOL-samples: non-processed (neat), hot-melt extruded at stress conditions (stressed) or hot-
melt extruded using different (low, medium and high) SME conditions (EX). The molecular structure of SOL is shown (right).   
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Figure 6. Off-line collected Raman spectra with first derivative pre-processing (upper figure) and the corresponding PC1 versus PC2 
scores plot (lower figure) of the calibration set for milled extrudates containing 5 % CEL (black), 10 % CEL (red), 20 % CEL (blue), 30 % 
CEL (yellow) and 40 % CEL (green). 
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Figure 7. Predicted versus observed CEL concentrations of the Raman spectra of the validation set containing 19 % CEL (black 
squares), 20 % CEL (red circles), 21 % CEL (blue triangles), 25 % CEL (yellow inverse triangles) and 35 % CEL (green diamond).  
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Figure 8. Tabletability plot of all experiments (left) and the effect plot including 95% confidence intervals of the tablet tensile strength at 255 MPa (right). 
Formulations without API (experiments 1-8) are represented by dotted lines (), formulations with 20 % drug load (experiments 9-16) are represented 
by full lines () while the centerpoints containing 10 % drug load (experiments 17-19) are displayed by dashed lines (-----).  
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Figure 9. Out-of-die elastic recovery in function of main compaction pressure for all experiments (left) and the corresponding effect plot
including 95% confidence intervals at 255 MPa (right). Formulations without API (experiments 1-8) are represented by dotted lines (), 
formulations with 20 % drug load (experiments 9-16) are represented by full lines () while the centerpoints containing 10 % drug load 
(experiments 17-19) are displayed by dashed lines (-----).  
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Figure 10. PC1 vs. PC2 bi-plot of the determined compaction and flow properties for formulations of experiments containing 20 % CEL (blue
triangles), formulations of experiments without drug load (orange boxes) and centerpoints containing 10 % CEL (green circles) for which the 
number represents the corresponding experiment number in the experimental design. The loadings (red star shape) represent the 
fragmentation factor (Db), the heckel value (Py), the plasticity factor (PF) and the anti-correlated in-die elastic recovery (IER), tablet tensile 
strength (TS) and out-of-die elastic recovery (AR) for three compaction pressures (low, medium, high) and the flow rate of the powder 
formulations.  
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Table 1. Overview of factor setting from the experimental design. 1055 
Table 2. Evaluation of the HME-process, extrudate and tablet properties from the experimental design. 1056 
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Table 3. Validation parameters of the Raman PLS model: trueness and precision indicating the accuracy of the method.  1058 
Table 4. Quantification of the CEL concentration (%) in extrudate powders of the correlating experiment (DOE) based on the 1059 
PLS model with an RMSEP of 1,84 %. 1060 
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Table 1. Overview of factor settings of the experimental design. 1105 
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Run 
 
Barrel T   
(°C) 
 
Screw speed 
(rpm) 
 
Throughput 
(kg/h) 
 
Drug load 
(%) 
1 160 50 0.2 0 
2 200 50 0.2 0 
3 160 200 0.2 0 
4 200 200 0.2 0 
5 160 50 0.5 0 
6 200 50 0.5 0 
7 160 200 0.5 0 
8 200 200 0.5 0 
9 160 50 0.2 20 
10 200 50 0.2 20 
11 160 200 0.2 20 
12 200 200 0.2 20 
13 160 50 0.5 20 
14 200 50 0.5 20 
15 160 200 0.5 20 
16 200 200 0.5 20 
17 180 125 0.35 10 
18 180 125 0.35 10 
19 180 125 0.35 10 
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Table 2. Evaluation of the HME-process, extrudate and tablet properties from the experimental design. 1156 
  1157 
 1158 
 1159 
 1160 
 1161 
 1162 
 1163 
 1164 
 1165 
 1166 
 1167 
 1168 
 1169 
 1170 
 1171 
 1172 
 1173 
 1174 
 1175 
 1176 
 1177 
 1178 
 1179 
 1180 
 1181 
 1182 
 1183 
 1184 
 1185 
 1186 
 1187 
 1188 
 1189 
 1190 
 1191 
 1192 
 1193 
 1194 
 1195 
 1196 
 1197 
 1198 
 1199 
 1200 
 1201 
Run HME-process  Extrudate properties  Tablet properties 
 Torque 
(%) 
SME 
(kWh/kg) 
 Tg 
(°C) 
d90 
(m) 
Moisture 
(%) 
True density 
(g/ml) 
 TS255 
(MPa) 
OER 
(%) 
PF 
(%) 
Py 
(MPa) 
1 48.5 0.18  60.8 64.3 2.08 1.183  3.26 14.6 91.0 60.8 
2 54.0 0.08  60.8 58.0 2.15 1.181  3.52 14.5 89.7 60.3 
3 42.5 0.63  58.5 50.8 2.05 1.181  3.56 14.6 88.8 54.4 
4 49.0 0.29  59.7 46.8 1.99 1.182  3.71 15.2 90.2 55.8 
5 26.5 0.04  57.8 78.9 2.14 1.179  3.62 15.4 91.0 62.4 
6 17.0 0.10  57.6 57.7 1.99 1.183  3.84 14.7 90.9 53.0 
7 12.5 0.05  58.7 64.8 2.18 1.186  3.62 16.0 90.3 55.6 
8 23.0 0.34  55.1 54.5 2.19 1.178  3.61 15.1 89.7 54.9 
9 23.5 0.09  56.9 114.3 1.86 1.215  4.67 10.4 91.6 73.0 
10 21.0 0.31  52.5 105.9 1.89 1.220  4.50 11.9 92.0 74.0 
11 29.0 0.04  54.1 108.8 2.05 1.221  4.42 11.3 91.6 74.5 
12 20.5 0.12  56.0 96.6 1.95 1.219  4.71 10.4 90.9 73.1 
13 6.5 0.02  55.9 102.9 1.37 1.220  4.50 11.5 90.1 75.7 
14 9.0 0.01  57.5 101.7 1.65 1.219  4.36 12.2 91.4 73.1 
15 9.0 0.13  57.0 96.0 1.51 1.220  4.59 11.3 91.9 76.4 
16 11.5 0.07  58.3 97.3 1.58 1.220  4.45 11.3 90.9 78.0 
17 19.0 0.10  57.8 68.2 2.01 1.200  3.89 13.5 90.8 67.9 
18 17.5 0.09  56.5 85.3 2.11 1.200  4.09 12.1 90.9 63.7 
19 18.0 0.10  60.6 68.3 2.05 1.197  4.08 12.5 91.7 69.9 
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Table 3. Validation parameters of the Raman PLS model: trueness and precision reflecting the accuracy of the quantification 1208 
method.   1209 
 1210 
 1211 
 1212 
 1213 
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 1216 
 1217 
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 1219 
 1220 
 1221 
 1222 
 1223 
 1224 
 1225 
 1226 
 1227 
 1228 
 1229 
 1230 
 1231 
 1232 
 1233 
 1234 
 1235 
 1236 
 1237 
 1238 
 1239 
 1240 
 1241 
 1242 
 1243 
 1244 
 1245 
 1246 
 1247 
 1248 
 1249 
 1250 
 1251 
Validation  
CEL concentration 
(%) 
Accuracy  
Trueness   
(% Relative bias) 
Precision  
(% RSD) 
19.0 -7.74 0.11 
20.0 -8.14 0.99 
21.0 -5.62 0.37 
25.0 -7.14 0.21 
35.0 -6.19 0.30 
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Table 4. Quantification of the CEL concentration (%) in the milled extrudates of the corresponding DOE experiment based on 1258 
the PLS model with an RMSEP of 1.84 %. 1259 
 1260 
 1261 
 Exp. N0 Conc. CEL (%) 
20
 %
 C
E
L 
(la
be
l c
la
im
) 
Exp. 9 
Exp. 10 
Exp. 11 
Exp. 12 
Exp. 13 
Exp. 14 
Exp. 15 
Exp. 16 
19.2  
20.3 
20.3 
20.0 
19.2 
19.4 
19.6 
19.8 
   
10
 %
 C
E
L 
(la
be
l c
la
im
) 
Exp. 17 
Exp. 18  
Exp. 19 
9.6 
9.8 
9.7 
